Browsing by Author "2d6d48d4-e5bf-401e-a354-c2a45326067e"
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Rule, S; Jurczak, W; Jerkeman, M; Rusconi, C; Trneny, M; Offner, F; Caballero, D; Joao, C; Witzens-Harig, M; Hess, G; Bence-Bruckler, I; Cho, S-G; Thieblemont, C; Zhou, W; Henninger, T; Goldberg, J; Vermeulen, J; Dreyling, M (2018-02-02)
Younes, A; Hilden, P; Coiffier, B; Hagenbeek, A; Salles, G; Wilson, W; Seymour, JF; Kelly, K; Gribben, J; Pfreunschuh, M; Morschhauser, F; Schoder, H; Zelenetz, AD; Rademaker, J; Advani, R; Valente, N; Fortpied, C; Witzig, TE; Sehn, LH; Engert, A; Fisher, RI; Zinzani, P-L; Federico, M; Hutchings, M; Bollard, C; Trneny, M; Elsayed, YA; Tobinai, K; Abramson, JS; Fowler, N; Goy, A; Smith, M; Ansell, S; Kuruvilla, J; Dreyling, M; Thieblemont, C; Little, RF; Aurer, I; Van Oers, MHJ; Takeshita, K; Gopal, A; Rule, S; de Vos, S; Kloos, I; Kaminski, MS; Meignan, M; Schwartz, LH; Leonard, JP; Schuster, SJ; Seshan, VE (England, 2017-07-01)In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel ...